NCT07171541 is a clinical trial of OCT ,mFERG,VA test in Macular Dystrophy, sponsored by New Valley University.

Who is sponsoring NCT07171541?

NCT07171541 is sponsored by New Valley University.

What drugs are being tested in NCT07171541?

Interventions in NCT07171541: OCT ,mFERG,VA test.

What condition does NCT07171541 study?

NCT07171541 studies Macular Dystrophy.

Is NCT07171541 still recruiting?

NCT07171541 is currently not yet recruiting. Last updated 12 September 2025.

Last reviewed 2025-09-12 · How we verify

NCT07171541

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Correlation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy

Not yet recruiting Last updated 12 September 2025

What this trial tests

trial testing OCT ,mFERG,VA test in Macular Dystrophy in 30 participants. Not yet recruiting.

Timeline

20 September 2025

Primary endpoint
20 November 2025

20 December 2025

Quick facts

Lead sponsor	New Valley University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	30
Start date	20 September 2025
Primary completion	20 November 2025
Estimated completion	20 December 2025

Drugs / interventions tested

OCT ,mFERG,VA test

Conditions studied

Macular Dystrophy — all drugs for Macular Dystrophy →

Sponsor

New Valley University

Who can join

Eligibility, any sex, with Macular Dystrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity in patients with macular dystrophy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other New Valley University trials

Trials by the same sponsor.

NCT06067399 — Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemi · recruiting
NCT06387667 — Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections · NA · not yet recruiting
NCT07142239 — Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome · not yet recruiting
NCT06490731 — Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients · Phase 1, PHASE2 · recruiting
NCT06697106 — Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy? · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07171541 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New Valley University
Last refreshed: 12 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07171541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing